Safety Outcomes During Pediatric GH Therapy: Final Results From the Prospective GeNeSIS Observational Program
Christopher J. Child(Eli Lilly (United Kingdom)), Werner Blum(Justus-Liebig-Universität Gießen), Cheri Deal(Centre Hospitalier Universitaire Sainte-Justine), Nan Jia(Eli Lilly (United States)), Mohamad Maghnie(Istituto Giannina Gaslini), Diego Yeste(Universitat Autònoma de Barcelona), Tohru Yorifuji(Osaka City General Hospital), George P. Chrousos(Academy of Athens), Annette Richter-Unruh, Agnès Linglart(Assistance Publique – Hôpitaux de Paris), Tomonobu Hasegawa, Sandro Loche(Ospedale Microcitemico), Elizabeth Cummings(Dalhousie University), Michel Polak(Délégation Paris 5), Sarah Lawrence(Children's Hospital of Eastern Ontario), Ron G. Rosenfeld(Oregon Health & Science University), Alan G. Zimmermann(Eli Lilly (United States)), Barbara Predieri(University of Modena and Reggio Emilia)
Cited by 77
Related Papers
Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I
|The Journal of Experimental Medicine|2010|721
Child Health, Developmental Plasticity, and Epigenetic Programming
|Endocrine Reviews|2010|625
Maternal body mass index, gestational weight gain, and the risk of overweight and obesity across childhood: An individual participant data meta-analysis
|PLoS Medicine|2019|523
Major Depression Is Associated with Significant Diurnal Elevations in Plasma Interleukin-6 Levels, a Shift of Its Circadian Rhythm, and Loss of Physiological Complexity in Its Secretion: Clinical Implications
|The Journal of Clinical Endocrinology & Metabolism|2005|376